Loading organizations...
Key people at RA Capital Advisors.
RA Capital Advisors is an investment banking firm specializing in mergers, acquisitions, and capital-raising for private companies. As an independent advocate, the firm guides first-time sellers through complex transactions, aiming to maximize value and optimize terms. Their approach is grounded in rigorous financial analysis, leveraging a senior team with accounting and due diligence expertise to streamline client operations.
Established in Delaware on December 2, 2002, RA Capital Advisors was founded by James Jeffrey Zehentbauer and Eliot Jerome Peters as key principals. Their insight recognized private business owners, particularly first-time sellers, require dedicated expert advisory for complex transactions. Zehentbauer’s prior investment management experience informed this client-centric approach.
RA Capital Advisors primarily serves private business owners, individuals, and families undertaking corporate transactions. The firm's vision is to deliver bespoke, results-driven guidance addressing clients' unique objectives. They aim to simplify daunting financial decisions, offering expertise and advocacy to empower private companies through strategic transitions.
Key people at RA Capital Advisors.
RA Capital Advisors has 1 tracked investment across 1 company. The latest tracked deal is $10.0M Series A in Tunitas Therapeutics in September 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 30, 2015 | Tunitas Therapeutics | $10.0M Series A | David Nikodem, Ph.d., Sofie Qiao | — |
RA Capital Management (accessible via racap.com) is a multi-stage investment manager focused on evidence-based investing in healthcare and life sciences, including company formation for drugs, medical devices, diagnostics, services, and research tools.[1][5] Its mission centers on driving value from idea inception through commercialization via seed funding, private rounds, IPOs, and follow-ons, supported by the TechAtlas division for scientific mapping, diligence, and ecosystem resources.[1][5] The firm targets global therapeutic areas across all stages, with a growing interest in climate and sustainability technologies, emphasizing collaborative, data-driven curiosity.[5]
A separate entity, RA Capital Advisors (raca.com), operates as a San Diego-based investment bank specializing in lower middle-market M&A ($10M-$500M deals), private financings, and advisory for private/family-owned businesses across industries.[2][3][4][7] Note: Search results distinguish these as distinct firms sharing similar branding; RA Capital Management leads in healthcare VC, while Advisors focuses on broad M&A.[1][2]
RA Capital Management was founded as a healthcare-focused investor and company builder, with managing partner Peter Kolchinsky authoring key books on biotech creation and societal value.[5][6] Its evolution emphasizes TechAtlas, an internal think tank launched for competitive mapping and industry analysis, which expanded during COVID-19 to publicly track global diagnostics/treatments.[1][6] The firm grew from diverse scientific backgrounds into a flexible, multi-stage player, prioritizing evidence over convention.[1][5]
RA Capital Advisors, regulated by FINRA in San Diego, emerged to serve first-time sellers—entrepreneurs and families—with a team of ex-CPAs and due diligence experts.[2][4][7] Key figures include principals Eliot Peters and Jim Zehentbauer; it handles selective, high-touch engagements like sell-side M&A and financings, building from a focus on private company needs.[2][4]
RA Capital Management rides the biotech/healthcare innovation wave, fueling company formation amid rising demand for novel therapies/devices amid aging populations and post-COVID R&D acceleration.[1][5][6] Its TechAtlas provides ecosystem-wide intelligence, influencing startups via resources and partnerships while advocating policy (e.g., drug affordability).[6] This positions it as a bridge from lab to market, amplifying life sciences impact.
RA Capital Advisors taps lower middle-market M&A trends, aiding private firms' exits/growth in fragmented sectors like SaaS and manufacturing amid economic consolidation.[2][3][4] By prioritizing independents, it democratizes access to sophisticated banking, supporting tech-adjacent transitions (e.g., cybersecurity, supply chain SaaS).[4]
RA Capital Management will likely deepen healthcare dominance while expanding climate tech, leveraging TechAtlas for AI-driven diligence amid precision medicine booms.[1][5] Evolving regulations and partnerships could amplify its builder role.
RA Capital Advisors may scale selective M&A as private markets mature, focusing on tech-enabled industries with recession-resilient deals.[2][4] Both entities' specialized models—evidence in health, advocacy in privates—poise them to shape innovation funding and exits, tying back to their core: turning ideas and businesses into enduring value.[1][2]
